Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO (Pfizer Press Release) - Sep 28, 2026 - "Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig (PF'4404)."
Clinical data • Castration-Resistant Prostate Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Non Small Cell Lung Cancer • Urothelial Cancer
|